Tiancheng Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tiancheng Luo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Haishu Chen
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, School of Mental Health, Wenzhou Medical University, Wenzhou 325035, China
1 shared publication - Hanyuan Xu
Institute of Albert, Wenzhou Medical University, Wenzhou 325035, China
1 shared publication - Jinan Xu
Beijing Geriatric Hospital, Beijing, China
1 shared publication - Ke Jiang
College of Teacher Education, Lishui University
1 shared publication - Yangping Shentu
Department of Pathology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication - Yihao Li
Institute of Albert, Wenzhou Medical University, Wenzhou 325035, China
1 shared publication
Latest Publications
- Open Access
- 3 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1133
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Alzheimer’s disease (AD), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (Aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. However, the developed medicines targeting Aβ and tau have not obtained ideal clinical efficacy, which raises a challenge to the hypothesis that AD is Aβ cascade-induced. A critical problem of AD pathogenesis is which endogenous factor induces Aβ aggregation and tau phosphorylation. Recently, age-associated endogenous formaldehyde has been suggested to be a direct trigger for Aβ- and tau-related pathology. Another key issue is whether or not AD drugs are successfully delivered to the damaged neurons. Both the blood–brain barrier (BBB) and extracellular space (ECS) are the barriers for drug delivery. Unexpectedly, Aβ-related SP deposition in ECS slows down or stops interstitial fluid drainage in AD, which is the direct reason for drug delivery failure. Here, we propose a new pathogenesis and perspectives on the direction of AD drug development and drug delivery: (1) aging-related formaldehyde is a direct trigger for Aβ assembly and tau hyperphosphorylation, and the new target for AD therapy is formaldehyde; (2) nano-packaging and physical therapy may be the promising strategy for increasing BBB permeability and accelerating interstitial fluid drainage.
- 3 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1133
Open AccessNew Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Alzheimer’s disease (AD), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (Aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. However, the developed medicines targeting Aβ and tau have not obtained ideal clinical efficacy, which raises a challenge to the hypothesis that AD is Aβ cascade-induced. A critical problem of AD pathogenesis is which endogenous factor induces Aβ aggregation and tau phosphorylation. Recently, age-associated endogenous formaldehyde has been suggested to be a direct trigger for Aβ- and tau-related pathology. Another key issue is whether or not AD drugs are successfully delivered to the damaged neurons. Both the blood–brain barrier (BBB) and extracellular space (ECS) are the barriers for drug delivery. Unexpectedly, Aβ-related SP deposition in ECS slows down or stops interstitial fluid drainage in AD, which is the direct reason for drug delivery failure. Here, we propose a new pathogenesis and perspectives on the direction of AD drug development and drug delivery: (1) aging-related formaldehyde is a direct trigger for Aβ assembly and tau hyperphosphorylation, and the new target for AD therapy is formaldehyde; (2) nano-packaging and physical therapy may be the promising strategy for increasing BBB permeability and accelerating interstitial fluid drainage.